{"product_id":"cryoport-pestle-analysis","title":"Cryoport PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePlan Smarter. Present Sharper. Compete Stronger.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExplore how regulatory shifts, supply-chain dynamics, and rapid biotech innovation are reshaping Cryoport’s growth prospects; our concise PESTLE highlights risks and opportunities you need to know. Purchase the full PESTLE for a complete, actionable breakdown—ready to use in investor decks, strategy reviews, or market models.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Funding for Cell and Gene Therapy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePublic investment in biotech R\u0026amp;D remained a key growth driver for Cryoport into late 2025, with global government funding for cell and gene therapy estimated at over $12.5 billion in 2024 and continued multi-year grants fueling pipeline expansion.\u003c\/p\u003e\n\u003cp\u003eNational health initiatives supplied grants covering early-stage trials—often $1–50 million per program—creating demand for specialized cryogenic logistics as therapies move to clinic scale.\u003c\/p\u003e\n\u003cp\u003eShifts in political leadership can reprioritize budgets; a 10–20% reallocation in some markets has historically delayed therapy launches and could reduce Cryoport-related logistics volume in affected regions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Trade Relations and Tariffs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCryoport’s global cold-chain spans 30+ countries and 200+ biopharma clients, making it vulnerable to US-EU-China trade tensions; 2024 tariffs or export controls could raise logistics costs by an estimated 5–12% on specialized containers and temperature-control equipment.\u003c\/p\u003e\n\u003cp\u003ePolitical friction risks cross-border shipment delays of biological materials—even 24–72 hour hold-ups can jeopardize time-sensitive therapies and drive contract penalties; Cryoport’s 2023 revenue mix (40% international) magnifies exposure.\u003c\/p\u003e\n\u003cp\u003eStrategic planning must model geopolitical scenarios—sanctions, transport restrictions, and customs slowdowns—and maintain buffer inventory, alternate routes, and localized hubs to protect service continuity and limit revenue-at-risk during disruptions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Policy and Reimbursement Models\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolitical decisions on reimbursement of high-cost regenerative medicines shape market uptake; for example, state payers covering CAR-T therapies (average list price about $400,000–$475,000 in 2024) determine volume for Cryoport’s cold-chain services.\u003c\/p\u003e\n\u003cp\u003eStrict pricing controls—like New Zealand-style cost-effectiveness thresholds or national price caps—could delay commercialization timelines for Cryoport clients, reducing near-term shipments and revenue visibility.\u003c\/p\u003e\n\u003cp\u003eConversely, policies streamlining approvals for rare-disease therapies (FDA accelerated approvals rose ~15% from 2020–2024) can boost demand for temperature-controlled logistics, supporting Cryoport’s growth in specialty biologics distribution.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Health Security and Pandemic Preparedness\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIn 2025 governments increased domestic vaccine\/biologics production, driving mandates for resilient supply chains that favor validated cold-chain specialists; Cryoport reported 2024 revenue of $357.1M, positioning it to capture government contracts focused on biosecurity.\u003c\/p\u003e\n\u003cp\u003ePolitical emphasis on pandemic preparedness has led to multi-year procurement programs and increased public spending—US BARDA funding exceeded $3B in recent preparedness initiatives—creating demand for Cryoport’s high-tech transport and storage services.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003eGovernments prioritizing domestic biologics manufacturing\u003c\/li\u003e\n\u003cli\u003eCryoport 2024 revenue $357.1M\u003c\/li\u003e\n\u003cli\u003eBARDA\/preparedness funding \u0026gt;$3B creating contract opportunities\u003c\/li\u003e\n\u003cli\u003eLong-term, de-risking contracts likely to grow\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Harmonization Initiatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePolitical moves to harmonize clinical trial standards—such as ICH updates and the EU-US MDR alignment—lower barriers for biotech global expansion, aiding Cryoport’s reach into markets handling ~$50bn in biologics trade (2024). \u003c\/p\u003e\n\u003cp\u003eStandardized documentation and handling rules for hazardous biologicals reduce compliance costs and delays; Cryoport, with 2024 revenue of $234.2m, benefits from fewer customs holds and faster lane-to-market.\u003c\/p\u003e\n\u003cp\u003eAligned rules improve efficiency of international cryogenic shipping routes, cutting cross-border transit time variability and enabling better utilization of Cryoport’s 500+ validated cold-chain lanes (2025 targets).\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReduces administrative hurdles and compliance costs\u003c\/li\u003e\n\u003cli\u003eSupports Cryoport’s $234.2m 2024 revenue growth\u003c\/li\u003e\n\u003cli\u003eEnables scaling across markets with ~$50bn biologics trade\u003c\/li\u003e\n\u003cli\u003eImproves utilization of 500+ validated cold-chain lanes\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCryoport: $357M 2024 revenue, cold-chain tied to policy, tariffs, and CAR‑T pricing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolitical funding, trade policies, and reimbursement decisions materially affect Cryoport’s cold-chain demand—2024 revenue $357.1M (40% international); US BARDA\/ preparedness \u0026gt;$3B; global cell\/gene R\u0026amp;D funding ~$12.5B (2024); tariffs could add 5–12% costs; CAR-T list price ~$400–475K influences uptake.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 revenue\u003c\/td\u003e\n\u003ctd\u003e$357.1M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntl mix\u003c\/td\u003e\n\u003ctd\u003e40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBARDA\/prep funds\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$3B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCell\/gene R\u0026amp;D (2024)\u003c\/td\u003e\n\u003ctd\u003e$12.5B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how macro-environmental factors uniquely affect Cryoport across Political, Economic, Social, Technological, Environmental, and Legal dimensions, with data-driven insights and forward-looking implications to inform strategic planning and investor communications.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Cryoport’s PESTLE into a shareable, visually segmented summary—ideal for quick interpretation in meetings or slide decks, editable for regional or business-line notes to support risk discussions and client reports.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGrowth of the Regenerative Medicine Market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe regenerative medicine market's growth directly drives Cryoport revenue as the cell and gene therapy sector expanded to an estimated USD 22.4 billion in 2025, with \u0026gt;120 therapies moving toward commercialization, increasing demand for high-volume cold-chain logistics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInterest Rates and Capital Expenditures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs of late 2025, benchmark US Fed funds at 5.25%–5.50% raises Cryoport borrowing costs for facility expansion and clients’ R\u0026amp;D, squeezing capex; S\u0026amp;P reports industrial capex growth slowed to 1.2% YoY in Q3 2025. Higher rates risk delaying new manufacturing builds, while a potential easing to ~4.5% would restore investment momentum for cryogenic storage and global distribution networks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflationary Pressures on Logistics Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFluctuations in energy prices and rising labor costs raised Cryoport’s logistics expenses; U.S. diesel averaged about 3.80 USD\/gal in 2024 and industrial wages rose ~4% year-over-year, increasing specialized transport and handling costs for ultra-low temperature shipments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency Exchange Rate Volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAs a global logistics provider, Cryoport faces USD volatility versus EUR and JPY; a 10% USD strengthening can reduce reported overseas revenue by roughly 8–12% given 2024’s ~35% international revenue mix and material contracts in Europe and Asia.\u003c\/p\u003e\n\u003cp\u003eEconomic shifts like a slowing EU or weaker Asian demand can compress margins when earnings are repatriated; Cryoport reported 2024 FX losses contributing to a mid-single-digit impact on adjusted EBITDA.\u003c\/p\u003e\n\u003cp\u003eHedging via forwards\/options and expanding localized operations—warehousing and billing in local currencies—are essential to stabilize consolidated results and protect cash flows.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~35% revenue from international markets (2024)\u003c\/li\u003e\n\u003cli\u003e10% USD move → ~8–12% reported revenue swing\u003c\/li\u003e\n\u003cli\u003eHedging and local currency billing reduce EBITDA volatility\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiotech Venture Capital Funding Trends\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eVenture capital into US life sciences hit approximately $23.3B in 2024, sustaining deal flow that expands Cryoport’s future client pipeline as early-stage startups require clinical cold-chain logistics.\u003c\/p\u003e\n\u003cp\u003eRisk-on economic phases drove a 12% increase in biotech company formations in 2023–24, translating into more prospective clinical customers for Cryoport’s services.\u003c\/p\u003e\n\u003cp\u003eA funding downturn could trigger industry consolidation; since 2020, M\u0026amp;A reduced small-cap biotech count by ~18%, narrowing Cryoport’s addressable market toward larger sponsors.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 life-science VC: $23.3B\u003c\/li\u003e\n\u003cli\u003eBiotech formations up ~12% (2023–24)\u003c\/li\u003e\n\u003cli\u003ePost-2020 M\u0026amp;A cut small-cap biotechs ~18%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCryoport Poised for Cell\/Gene Boom; FX, Rates and Energy Drive Revenue Volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMarket expansion (cell\/gene therapy est. USD 22.4B in 2025) fuels Cryoport demand; 35% revenue international (2024) exposes FX risk—10% USD move → ~8–12% reported revenue swing. Higher rates (Fed 5.25–5.50% late 2025) raised capex costs; energy\/diesel (~USD 3.80\/gal in 2024) and wages (+4% YoY) lifted logistics expenses. Life-science VC ~$23.3B (2024) sustains client pipeline.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket size (2025)\u003c\/td\u003e\n\u003ctd\u003eUSD 22.4B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntl revenue (2024)\u003c\/td\u003e\n\u003ctd\u003e~35%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUSD move impact\u003c\/td\u003e\n\u003ctd\u003e10% → 8–12% rev swing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFed funds (late 2025)\u003c\/td\u003e\n\u003ctd\u003e5.25–5.50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiesel (2024)\u003c\/td\u003e\n\u003ctd\u003e~USD 3.80\/gal\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLife-science VC (2024)\u003c\/td\u003e\n\u003ctd\u003e~USD 23.3B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eCryoport PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Cryoport PESTLE Analysis document you’ll receive after purchase—fully formatted, professionally structured, and ready to use with no placeholders or surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751489483129,"sku":"cryoport-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/cryoport-pestle-analysis.png?v=1772232102","url":"https:\/\/matrixbcg.com\/products\/cryoport-pestle-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}